ダウンロード数: 206
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
41_191.pdf | 324.08 kB | Adobe PDF | 見る/開く |
タイトル: | LH-RH analogue初回投与時のFlare-up予防に関するDiethylstilbestrol併用投与の効果について |
その他のタイトル: | Study on prevention of flare-up phenomenon following initial LH-RH analogue administration: combination therapy with diethylstilbestrol |
著者: | 竹内, 信一 吉田, 謙一郎 遠坂, 顕 小林, 信幸 東, 四雄 根岸, 壮治 |
著者名の別形: | Takeuchi, Shin-ichi Yoshida, Ken-ichiro Tosaka, Akira Kobayashi, Nobuyuki Higashi, Yotsuo Negishi, Takeharu |
キーワード: | Diethylstilbestrol LH-RH analogue Prostate carcinoma Flare-up |
発行日: | Mar-1995 |
出版者: | 泌尿器科紀要刊行会 |
誌名: | 泌尿器科紀要 |
巻: | 41 |
号: | 3 |
開始ページ: | 191 |
終了ページ: | 196 |
抄録: | 進行前立腺癌16例に対して, LH-RH analogue初回投与時のflare-upを予防する目的で, DES 500mg/dayを前投与, 同時投与などの4群に分け施行した。LH-RH analogue初回投与時のflare-up予防にはDES 500mg/dayをLH-RH analogue投与前7日から投与後3日まで投与すれば十分である To eliminate the initial testosterone (T) surge and prevent the risk of flare-up induced by the first administration of luteinizing hormone-releasing hormone (LH-RH) analogue, we examined the effectiveness of short-term combination therapy with diethylstilbestrol (DES). Sixteen previously untreated patients with prostate carcinoma (Stage C: 4 cases, Stage D2: 12 cases) were randomly assigned to 4 groups. Each group included 4 patients. Group 1 received DES (500 mg daily injection) for 7 days, staring before the first subcutaneous injection of luteinizing hormone releasing hormone (LH-RH) analogue (3.6 mg of Zoladex depot); Group 2 received 500 mg of DES injection for 7 days prior to the initiation of therapy with the LH-RH analogue, and moreover received a DES injection for 7 days; Group 3 received 500 mg of DES injection for 7 days simultaneously with the first injection of the LH-RH analogue; Group 4 was pretreated with 500 mg of DES injection for 7 days prior to the initiation of therapy with the LH-RH analogue, with additional DES injection for 3 days. In groups 1, 2 and 4 the level of T decreased during the 7 days of DES therapy, and at 3 days after the first injection of LH-RH analogue increased again. The mean T value in groups 1, 2 and 4 decreased by 33.2 +/- 27.6% (mean +/- SE), 20.5 +/- 20.8%, 13.2 +/- 9.8%, respectively, at the day of the first injection of LH-RH analogue, and increased by 75.2 +/- 21.6%, 70.7 +/- 63.4%, 56.7 +/- 46.4%, respectively, at 3 days after the first injection of LH-RH analogue.(ABSTRACT TRUNCATED AT 250 WORDS) |
URI: | http://hdl.handle.net/2433/115467 |
PubMed ID: | 7741071 |
出現コレクション: | Vol.41 No.3 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。